CA1148546A - Uracil derivatives, process for preparing the same and a pharmaceutical composition containing the same - Google Patents

Uracil derivatives, process for preparing the same and a pharmaceutical composition containing the same

Info

Publication number
CA1148546A
CA1148546A CA000383943A CA383943A CA1148546A CA 1148546 A CA1148546 A CA 1148546A CA 000383943 A CA000383943 A CA 000383943A CA 383943 A CA383943 A CA 383943A CA 1148546 A CA1148546 A CA 1148546A
Authority
CA
Canada
Prior art keywords
group
formula
process according
fluorouracil
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000383943A
Other languages
English (en)
French (fr)
Inventor
Kiyoshige Ochi
Katsuhito Miyamoto
Hiroki Mitsui
Shigeru Takanashi
Takashi Matsuno
Yumiko Tsuruma
Isao Matsunaga
Minoru Shindo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of CA1148546A publication Critical patent/CA1148546A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA000383943A 1980-08-19 1981-08-14 Uracil derivatives, process for preparing the same and a pharmaceutical composition containing the same Expired CA1148546A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP112993/1980 1980-08-19
JP11299380A JPS5738774A (en) 1980-08-19 1980-08-19 Uracil derivative and its preparation

Publications (1)

Publication Number Publication Date
CA1148546A true CA1148546A (en) 1983-06-21

Family

ID=14600731

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000383943A Expired CA1148546A (en) 1980-08-19 1981-08-14 Uracil derivatives, process for preparing the same and a pharmaceutical composition containing the same

Country Status (6)

Country Link
US (1) US4415573A (cg-RX-API-DMAC10.html)
EP (1) EP0046307B1 (cg-RX-API-DMAC10.html)
JP (1) JPS5738774A (cg-RX-API-DMAC10.html)
AT (1) ATE10368T1 (cg-RX-API-DMAC10.html)
CA (1) CA1148546A (cg-RX-API-DMAC10.html)
DE (1) DE3167320D1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5839672A (ja) * 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd ウラシル誘導体
DK160271C (da) * 1982-09-17 1991-07-22 Glaxo Group Ltd Analogifremgangsmaade til fremstilling af 5-halogenvinyl-uracil-derivater
SU1235864A1 (ru) * 1983-03-11 1986-06-07 Отделение ордена Ленина института химической физики АН СССР Нитроксильные производные 5-фторурацила,обладающие противоопухолевой активностью
JPS61204190A (ja) * 1985-03-06 1986-09-10 Kanto Ishi Pharma Co Ltd グリコシド及びその製造方法
US4719214A (en) * 1985-07-25 1988-01-12 Southern Research Institute Carbocyclic analogues of thymine nucleosides
US4613604A (en) * 1985-07-31 1986-09-23 Brown University Research Foundation Hydroxymethyl derivatives of 5-benzylacyclouridine and 5-benzoyloxybenzylacyclouridine and their use as potentiators for 5-fluoro-2'-deoxyuridine
JPS62174060A (ja) * 1985-10-11 1987-07-30 Terumo Corp ５−フルオロウラシル誘導体およびこれを含有する医薬製剤
HU206328B (en) * 1988-03-31 1992-10-28 Mitsubishi Chem Ind Process for producing 6-substituted pyrimidine derivatives and antiviral phqrmaceutical compositions containing them as active components
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
EP0425669B1 (en) * 1988-07-18 1995-01-25 Yamasa Shoyu Kabushiki Kaisha also trading as Yamasa Corporation 1-amino-5-halogenouracils, process for their preparation, and central nervous system depressants containing same as active ingredient
DE3905725A1 (de) * 1989-02-24 1990-09-06 Boehringer Mannheim Gmbh Seco-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung als antivirale mittel
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
DE69430587T2 (de) * 1994-02-28 2003-01-09 Sunkyong Industries Co. Ltd., Suwon Pyrimidin-acyclonukleosid-derivate
NZ513094A (en) * 1998-12-23 2004-05-28 Shire Biochem Inc Antiviral nucleoside analogues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947444A (en) * 1973-06-21 1976-03-30 Solomon Aronovich Giller Process for producing N1 -(Dihydroxyalkyl)-5-substituted uracils
JPS606943B2 (ja) * 1975-04-01 1985-02-21 三井製薬工業株式会社 １−（α−アルコキシアルキル）−ウラシル類の製造法
JPS609505B2 (ja) * 1976-04-20 1985-03-11 大鵬薬品工業株式会社 ５−フルオルウラシル誘導体
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
JPS6011704B2 (ja) * 1976-07-30 1985-03-27 大鵬薬品工業株式会社 ５−フルオルウラシル誘導体の製造法
JPS5331676A (en) * 1976-09-06 1978-03-25 Mitsui Toatsu Chem Inc Uracil derivatives and their preparation
CH633280A5 (de) * 1978-03-09 1982-11-30 Elkawi Ag 5-fluoruracil-derivate und diese verbindungen enthaltende arzneimittel.

Also Published As

Publication number Publication date
DE3167320D1 (en) 1985-01-03
JPH0140830B2 (cg-RX-API-DMAC10.html) 1989-08-31
EP0046307B1 (en) 1984-11-21
EP0046307A1 (en) 1982-02-24
ATE10368T1 (de) 1984-12-15
JPS5738774A (en) 1982-03-03
US4415573A (en) 1983-11-15

Similar Documents

Publication Publication Date Title
CA1148546A (en) Uracil derivatives, process for preparing the same and a pharmaceutical composition containing the same
US5075445A (en) Guanine derivatives
KR970009223B1 (ko) 비스(히드록시메틸)시클로부틸 푸린 및 피리미딘
US4855466A (en) Purinyl cyclobutanes
KR960009434B1 (ko) 3-데메틸메발론산 유도체, 이의 제조방법 및 중간체
KR920000908B1 (ko) 나프탈렌 유도체
US4605659A (en) Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals
US5246937A (en) Purine derivatives
JPH0542438B2 (cg-RX-API-DMAC10.html)
CA1334535C (en) 6-substituted acyclopyrimidine nucleoside derivative and antiviral agent containing the same as active ingredient thereof
KR100232619B1 (ko) 사이클로프로판 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
CA1262897A (en) Production of cytosine nucleosides
US3868373A (en) 4-Amino-5-fluoro-2-tri(lower alkyl) silyloxypyrimidines
EP0458363B1 (en) Fluorinated bis(hydroxymethyl) cyclobutyl purines and pyrimidines
US3721664A (en) Preparation of 5-cytosine nucleosides
EP0103551A2 (en) Novel derivatives of guanine
US4115650A (en) Process for preparing 2,4-diamino-5-(substituted benzyl)-pyrimidines
US4060616A (en) Purine derivatives with repeating unit
EP0464769B1 (en) Purinyl and pyrimidinyl tetrahydrofurans
US6034087A (en) Nucleoside derivatives and process for preparing thereof
USH1142H (en) Optically active cyclobutyl pyrimidine
AU642504B2 (en) A process for the preparation of substituted acyclic nucleosides, and intermediates occurring therein
JPH07126282A (ja) 新規なチオヌクレオシド誘導体
US5272152A (en) Purinyl and pyrimidinyl tetrahydrofurans
JP2654994B2 (ja) ５´―置換―５―フルオロウリジン誘導体

Legal Events

Date Code Title Description
MKEX Expiry